z-logo
open-access-imgOpen Access
Alicaforsen: An Emerging Therapeutic Agent for Ulcerative Colitis and Refractory Pouchitis
Author(s) -
Hosten
Publication year - 2014
Publication title -
gastroenterology research
Language(s) - English
Resource type - Journals
eISSN - 1918-2813
pISSN - 1918-2805
DOI - 10.14740/gr599w
Subject(s) - pouchitis , ulcerative colitis , medicine , refractory (planetary science) , pouch , gastroenterology , anastomosis , colitis , intensive care medicine , surgery , disease , physics , astrobiology
Pouchitis is a relatively common complication that develops following ileal pouch-anal anastomosis in patients with complicated ulcerative colitis (UC). Both pouchitis and UC share similarities in their development, as well as in the mechanisms involving mediators of the inflammatory process. In the recent years, the discovery and investigation of biological therapies have led to advancement in the management of these disorders, and the continuation of research on this novel area holds strong implications for a future reduction in the use of invasive surgical procedures. Alicaforsen represents one of these emerging therapeutic agents, and has demonstrated promising results in both preclinical and clinical settings. This article reviews the therapeutic effects of alicaforsen for the management of UC and refractory pouchitis, with special emphasis on the mechanism of action of this therapeutic agent and the clinical studies asserting its effectiveness.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here